• Citer

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

par Loibl, Sibylle;Von Minckwitz, Gunter;Schneeweiss, Andreas;Paepke, Stefan;Lehmann, Annika;Rezai, Mahdi;Zahm, Dirk DM;Sinn, Peter;Khandan, Fariba;Eidtmann, Holger;Dohnal, Karel;Heinrichs, Clemens;Huober, Jens;Pfitzner, Berit BM;Fasching, Peter A;Andre, Fabrice;Lindner, Judith JL;Sotiriou, Christos ;Dykgers, August;Guo, Sanxing;Gade, Stephan;Nekljudova, Valentina;Loi, Sherene ;Untch, Michael;Denkert, Carsten
Référence Journal of clinical oncology, 32, 29, page (3212-3220)
Publication Publié, 2014-10

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in breast cancer, with mutations in PIK3CA being the most common. This study investigated the association between PIK3CA genotype and pathologic complete response (pCR) rates in human epidermal growth factor receptor 2 (HER2)-positive breast cancer treated with either dual or single anti-HER2 treatment in addition to neoadjuvant chemotherapy.